Kura Oncology Stock Price, News & Analysis (NASDAQ:KURA)

$22.75 +0.60 (+2.71 %)
(As of 02/23/2018 04:00 PM ET)
Previous Close$22.75
Today's Range$22.00 - $23.15
52-Week Range$5.90 - $24.02
Volume308,108 shs
Average Volume421,317 shs
Market Capitalization$706.02 million
P/E Ratio-14.68
Dividend YieldN/A
BetaN/A

About Kura Oncology (NASDAQ:KURA)

Kura Oncology logoKura Oncology, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small molecule product candidates that targets cell-signaling pathways, which drives the progression of certain cancers. It is developing its lead product candidate, tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and blood cancers. It is advancing KO-947, a small molecule inhibitor of extracellular-signal-regulated kinase (ERK), as a treatment for patients with tumors that have mutations in or other dysregulation of the mitogen-activated protein kinase (MAPK), signaling pathway, including pancreatic cancer, colorectal cancer, non-small cell lung cancer (NSCLC) and melanoma.

Receive KURA News and Ratings via Email

Sign-up to receive the latest news and ratings for KURA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorHealthcare
SymbolNASDAQ:KURA
CUSIPN/A
Phone+1-858-5008800

Debt

Debt-to-Equity Ratio0.07%
Current Ratio13.48%
Quick Ratio13.48%

Price-To-Earnings

Trailing P/E Ratio-14.6774193548387
Forward P/E Ratio-15.17
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$2.66 per share
Price / Book8.55

Profitability

Trailing EPS($1.55)
Net Income$-27,560,000.00
Net MarginsN/A
Return on Equity-53.40%
Return on Assets-44.08%

Miscellaneous

Employees25
Outstanding Shares30,220,000

Kura Oncology (NASDAQ:KURA) Frequently Asked Questions

What is Kura Oncology's stock symbol?

Kura Oncology trades on the NASDAQ under the ticker symbol "KURA."

How were Kura Oncology's earnings last quarter?

Kura Oncology, Inc. (NASDAQ:KURA) released its earnings results on Tuesday, November, 7th. The company reported ($0.38) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.37) by $0.01. View Kura Oncology's Earnings History.

When will Kura Oncology make its next earnings announcement?

Kura Oncology is scheduled to release their next quarterly earnings announcement on Monday, March, 12th 2018. View Earnings Estimates for Kura Oncology.

Where is Kura Oncology's stock going? Where will Kura Oncology's stock price be in 2018?

6 analysts have issued twelve-month price targets for Kura Oncology's shares. Their predictions range from $18.00 to $30.00. On average, they expect Kura Oncology's share price to reach $22.60 in the next year. View Analyst Ratings for Kura Oncology.

What are Wall Street analysts saying about Kura Oncology stock?

Here are some recent quotes from research analysts about Kura Oncology stock:

  • 1. Cann analysts commented, "Kura announced positive updated preliminary results from its phase II study of tipifarnib in patients with HRAS mutant head and neck squamous cell carcinoma (HNSCC) were presented at the 2018 Multidisciplinary Head and Neck Cancers Symposium. Kura Oncology reiterated that it expects to initiate a registrational study of tipifarnib in HRAS mutant HNSCC sometime in 2018. These data combined with the 2017 ASH data, and a patent issued for tipifarnib earlier this year, are leading us to increase our estimated potential price for tipifarnib. This increases our estimated revenue in 2020-2022 by 66.7% per year, and is leading us to increase our price target to $30 per share (from $17.50)." (2/16/2018)
  • 2. According to Zacks Investment Research, "Kura Oncology, Inc. is a biopharmaceutical company. The company is involved in the discovery and development of therapeutics for the treatment of tumors and blood cancers. Its product pipeline includes small molecule drug candidates which are in different clinical trial consists of Tipifarnib-HRAS, Tipifarnib-PTCL, ERK inhibitor program and Menin MLL inhibitor program. Kura Oncology, Inc. is headquartered in La Jolla, California. " (2/8/2018)

Who are some of Kura Oncology's key competitors?

Who are Kura Oncology's key executives?

Kura Oncology's management team includes the folowing people:

  • Troy E. Wilson Ph.D. J.D., Chairman of the Board, President, Chief Executive Officer (Age 48)
  • Heidi Henson CPA, Chief Financial Officer, Secretary (Age 50)
  • Annette North, Senior Vice President, General Counsel (Age 49)
  • Pingda Ren Ph.D., Senior Vice President - Chemistry and Pharmaceutical Sciences (Age 46)
  • Liu Yi Ph.D., Chief Scientific Officer (Age 47)
  • Antonio Gualberto M.D. Ph.D., Chief Medical Officer (Age 50)
  • Steven H. Stein M.D., Director (Age 50)
  • Faheem Hasnain, Independent Director (Age 58)
  • Robert E. Hoffman, Independent Director (Age 51)
  • Thomas R. Malley, Independent Director (Age 47)

Who owns Kura Oncology stock?

Kura Oncology's stock is owned by many different of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (5.05%), Candriam Luxembourg S.C.A. (1.70%), Nexthera Capital LP (1.47%), Millennium Management LLC (1.01%), Minerva Advisors LLC (0.57%) and Geode Capital Management LLC (0.55%). View Institutional Ownership Trends for Kura Oncology.

Who sold Kura Oncology stock? Who is selling Kura Oncology stock?

Kura Oncology's stock was sold by a variety of institutional investors in the last quarter, including Bank of Montreal Can, Renaissance Technologies LLC, Deutsche Bank AG, Minerva Advisors LLC, Candriam Luxembourg S.C.A. and Metropolitan Life Insurance Co. NY. View Insider Buying and Selling for Kura Oncology.

Who bought Kura Oncology stock? Who is buying Kura Oncology stock?

Kura Oncology's stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Nexthera Capital LP, Millennium Management LLC, Lazard Asset Management LLC, Bailard Inc., Alps Advisors Inc., Wells Fargo & Company MN and California Public Employees Retirement System. View Insider Buying and Selling for Kura Oncology.

How do I buy Kura Oncology stock?

Shares of Kura Oncology can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Kura Oncology's stock price today?

One share of Kura Oncology stock can currently be purchased for approximately $22.75.

How big of a company is Kura Oncology?

Kura Oncology has a market capitalization of $706.02 million. The company earns $-27,560,000.00 in net income (profit) each year or ($1.55) on an earnings per share basis. Kura Oncology employs 25 workers across the globe.

How can I contact Kura Oncology?

Kura Oncology's mailing address is 3033 Science Park Rd Ste 220, SAN DIEGO, CA 92121-1166, United States. The company can be reached via phone at +1-858-5008800 or via email at [email protected]


MarketBeat Community Rating for Kura Oncology (KURA)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  153 (Vote Outperform)
Underperform Votes:  126 (Vote Underperform)
Total Votes:  279
MarketBeat's community ratings are surveys of what our community members think about Kura Oncology and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Kura Oncology (NASDAQ:KURA) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $22.60$18.30$17.75$15.75
Price Target Upside: 7.36% upside16.19% upside14.15% upside73.08% upside

Kura Oncology (NASDAQ:KURA) Consensus Price Target History

Price Target History for Kura Oncology (NASDAQ:KURA)

Kura Oncology (NASDAQ:KURA) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/16/2018CannReiterated RatingBuy$30.00HighView Rating Details
2/16/2018CitigroupSet Price TargetBuy$28.00HighView Rating Details
12/26/2017WedbushInitiated CoverageBuy$19.00MediumView Rating Details
12/11/2017OppenheimerSet Price TargetBuy$18.00HighView Rating Details
9/7/2017CowenInitiated CoverageOutperformMediumView Rating Details
8/10/2017Leerink SwannReiterated RatingOutperform$16.00 -> $18.00HighView Rating Details
(Data available from 2/24/2016 forward)

Earnings

Kura Oncology (NASDAQ:KURA) Earnings History and Estimates Chart

Earnings by Quarter for Kura Oncology (NASDAQ:KURA)

Kura Oncology (NASDAQ KURA) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/12/2018($0.36)N/AView Earnings Details
11/7/2017Q3 2017($0.37)($0.38)ViewN/AView Earnings Details
8/7/2017Q2 2017($0.43)($0.40)ViewListenView Earnings Details
5/15/2017Q1 2017($0.44)($0.39)ViewN/AView Earnings Details
3/14/2017Q4 2016($0.41)($0.38)ViewN/AView Earnings Details
11/7/2016Q3($0.41)($0.37)ViewListenView Earnings Details
8/10/2016Q2($0.34)($0.36)ViewListenView Earnings Details
5/11/2016Q1($0.35)($0.36)ViewN/AView Earnings Details
3/17/2016Q4($0.44)($0.42)ViewListenView Earnings Details
11/13/2015Q3 2015($0.42)($0.57)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Kura Oncology (NASDAQ:KURA) Earnings Estimates

2018 EPS Consensus Estimate: ($1.77)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20183($0.48)($0.30)($0.40)
Q2 20183($0.49)($0.31)($0.42)
Q3 20183($0.63)($0.35)($0.48)
Q4 20183($0.59)($0.40)($0.47)
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Kura Oncology (NASDAQ:KURA)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Kura Oncology (NASDAQ KURA)

No insider trades for this company have been tracked by MarketBeat.com

Headlines

Kura Oncology (NASDAQ KURA) News Headlines

Source:
DateHeadline
Kura Oncology, Inc. (KURA) Given Average Rating of "Buy" by AnalystsKura Oncology, Inc. (KURA) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - February 23 at 1:44 AM
Who Are The Major Shareholders Of Kura Oncology Inc (NASDAQ:KURA)?Who Are The Major Shareholders Of Kura Oncology Inc (NASDAQ:KURA)?
finance.yahoo.com - February 20 at 9:15 AM
Oppenheimer Comments on Kura Oncology, Inc.s FY2022 Earnings (KURA)Oppenheimer Comments on Kura Oncology, Inc.'s FY2022 Earnings (KURA)
www.americanbankingnews.com - February 19 at 9:18 AM
FY2022 Earnings Estimate for Kura Oncology, Inc. Issued By Wedbush (KURA)FY2022 Earnings Estimate for Kura Oncology, Inc. Issued By Wedbush (KURA)
www.americanbankingnews.com - February 19 at 9:18 AM
Kura Oncology, Inc. Forecasted to Post Q1 2018 Earnings of ($0.30) Per Share (KURA)Kura Oncology, Inc. Forecasted to Post Q1 2018 Earnings of ($0.30) Per Share (KURA)
www.americanbankingnews.com - February 19 at 2:18 AM
-$0.36 EPS Expected for Kura Oncology, Inc. (KURA) This Quarter-$0.36 EPS Expected for Kura Oncology, Inc. (KURA) This Quarter
www.americanbankingnews.com - February 16 at 5:12 PM
Brokers Issue Forecasts for Kura Oncology, Inc.s Q4 2018 Earnings (KURA)Brokers Issue Forecasts for Kura Oncology, Inc.'s Q4 2018 Earnings (KURA)
www.americanbankingnews.com - February 16 at 2:02 PM
Kura Oncology (KURA) Price Target Increased to $28.00 by Analysts at CitigroupKura Oncology (KURA) Price Target Increased to $28.00 by Analysts at Citigroup
www.americanbankingnews.com - February 16 at 11:24 AM
Kura Oncology (KURA) Stock Rating Reaffirmed by CannKura Oncology (KURA) Stock Rating Reaffirmed by Cann
www.americanbankingnews.com - February 16 at 11:24 AM
Kura Oncology (KURA) Upgraded by Zacks Investment Research to HoldKura Oncology (KURA) Upgraded by Zacks Investment Research to Hold
www.americanbankingnews.com - February 8 at 12:09 PM
Kura Oncology to Present at the Leerink Partners 7th Annual Global Healthcare ConferenceKura Oncology to Present at the Leerink Partners 7th Annual Global Healthcare Conference
finance.yahoo.com - February 8 at 9:02 AM
Kura Oncology, Inc. (KURA) Given Average Recommendation of "Buy" by BrokeragesKura Oncology, Inc. (KURA) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - January 29 at 1:28 AM
Kura Oncology (KURA) Upgraded by BidaskClub to "Buy"Kura Oncology (KURA) Upgraded by BidaskClub to "Buy"
www.americanbankingnews.com - January 29 at 12:28 AM
Kura Oncology (KURA) versus Its Rivals Critical SurveyKura Oncology (KURA) versus Its Rivals Critical Survey
www.americanbankingnews.com - January 4 at 1:32 PM
Kura Oncology, Inc. (KURA) Receives Average Recommendation of "Buy" from AnalystsKura Oncology, Inc. (KURA) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - January 4 at 2:02 AM
Does Kura Oncology Inc’s (NASDAQ:KURA) CEO Pay Reflect Performance?Does Kura Oncology Inc’s (NASDAQ:KURA) CEO Pay Reflect Performance?
finance.yahoo.com - January 3 at 4:44 PM
Wedbush Begins Coverage on Kura Oncology (KURA)Wedbush Begins Coverage on Kura Oncology (KURA)
www.americanbankingnews.com - December 29 at 7:58 PM
Reviewing Kura Oncology (KURA) and Its CompetitorsReviewing Kura Oncology (KURA) and Its Competitors
www.americanbankingnews.com - December 29 at 3:28 AM
Zacks: Analysts Expect Kura Oncology, Inc. (KURA) to Post -$0.36 Earnings Per ShareZacks: Analysts Expect Kura Oncology, Inc. (KURA) to Post -$0.36 Earnings Per Share
www.americanbankingnews.com - December 28 at 1:08 AM
All You Need To Know About Kura Oncology Inc’s (NASDAQ:KURA) RisksAll You Need To Know About Kura Oncology Inc’s (NASDAQ:KURA) Risks
finance.yahoo.com - December 27 at 2:36 PM
Head to Head Review: Kura Oncology (KURA) & Its CompetitorsHead to Head Review: Kura Oncology (KURA) & Its Competitors
www.americanbankingnews.com - December 26 at 6:18 PM
Wedbush Comments on Kura Oncology, Inc.s FY2017 Earnings (KURA)Wedbush Comments on Kura Oncology, Inc.'s FY2017 Earnings (KURA)
www.americanbankingnews.com - December 25 at 2:28 AM
Head to Head Review: Kura Oncology (KURA) and Its PeersHead to Head Review: Kura Oncology (KURA) and Its Peers
www.americanbankingnews.com - December 24 at 8:05 AM
Kura Oncology (KURA) Rating Increased to Hold at BidaskClubKura Oncology (KURA) Rating Increased to Hold at BidaskClub
www.americanbankingnews.com - December 23 at 1:28 PM
Wedbush Rates Kura Oncology Outperform As Catalysts LoomWedbush Rates Kura Oncology Outperform As Catalysts Loom
finance.yahoo.com - December 22 at 10:22 AM
Kura Oncology (KURA) Research Coverage Started at WedbushKura Oncology (KURA) Research Coverage Started at Wedbush
www.americanbankingnews.com - December 20 at 5:12 PM
Kura Oncology Added to Nasdaq Biotechnology IndexKura Oncology Added to Nasdaq Biotechnology Index
finance.yahoo.com - December 18 at 10:37 AM
Head to Head Comparison: Kura Oncology (KURA) & Its CompetitorsHead to Head Comparison: Kura Oncology (KURA) & Its Competitors
www.americanbankingnews.com - December 16 at 3:24 PM
Kura Oncology (KURA) vs. Its Rivals Head to Head SurveyKura Oncology (KURA) vs. Its Rivals Head to Head Survey
www.americanbankingnews.com - December 16 at 11:30 AM
What Is The Future Prospect For Healthcare And Kura Oncology Inc (undefined:KURA)?What Is The Future Prospect For Healthcare And Kura Oncology Inc (undefined:KURA)?
finance.yahoo.com - December 12 at 4:59 PM
Oppenheimer Analysts Give Kura Oncology (KURA) a $18.00 Price TargetOppenheimer Analysts Give Kura Oncology (KURA) a $18.00 Price Target
www.americanbankingnews.com - December 12 at 8:48 AM
Cann Reaffirms Buy Rating for Kura Oncology (KURA)Cann Reaffirms Buy Rating for Kura Oncology (KURA)
www.americanbankingnews.com - December 11 at 4:28 PM
Comparing Kura Oncology (KURA) & The CompetitionComparing Kura Oncology (KURA) & The Competition
www.americanbankingnews.com - December 11 at 5:38 AM
Kura Oncology Reports Positive Phase 2 Study of Tipifarnib in Chronic Myelomonocytic LeukemiaKura Oncology Reports Positive Phase 2 Study of Tipifarnib in Chronic Myelomonocytic Leukemia
finance.yahoo.com - December 10 at 10:07 AM
Kura Oncology, Inc. (KURA) Receives Average Recommendation of "Hold" from BrokeragesKura Oncology, Inc. (KURA) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - December 10 at 1:52 AM
Kura Oncology (KURA) and The Competition Head-To-Head AnalysisKura Oncology (KURA) and The Competition Head-To-Head Analysis
www.americanbankingnews.com - December 10 at 1:30 AM
Head to Head Analysis: Kura Oncology (KURA) vs. Its PeersHead to Head Analysis: Kura Oncology (KURA) vs. Its Peers
www.americanbankingnews.com - December 9 at 9:10 PM
Kura Oncology (KURA) Downgraded by BidaskClub to SellKura Oncology (KURA) Downgraded by BidaskClub to Sell
www.americanbankingnews.com - December 7 at 11:52 PM
Kura Oncology (KURA) and Its Competitors Critical ComparisonKura Oncology (KURA) and Its Competitors Critical Comparison
www.americanbankingnews.com - December 6 at 3:08 PM
Kura Oncology (KURA) Downgraded to "Sell" at ValuEngineKura Oncology (KURA) Downgraded to "Sell" at ValuEngine
www.americanbankingnews.com - December 3 at 8:34 AM
-$0.34 EPS Expected for Kura Oncology, Inc. (KURA) This Quarter-$0.34 EPS Expected for Kura Oncology, Inc. (KURA) This Quarter
www.americanbankingnews.com - November 22 at 7:10 PM
Oppenheimer Holdings, Inc. Reiterates "$18.00" Price Target for Kura Oncology, Inc. (KURA)Oppenheimer Holdings, Inc. Reiterates "$18.00" Price Target for Kura Oncology, Inc. (KURA)
www.americanbankingnews.com - November 18 at 1:38 PM
Kura Oncology, Inc. (KURA) Receives Consensus Recommendation of "Buy" from AnalystsKura Oncology, Inc. (KURA) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - November 15 at 1:46 AM
Short Interest in Kura Oncology, Inc. (KURA) Rises By 36.6%Short Interest in Kura Oncology, Inc. (KURA) Rises By 36.6%
www.americanbankingnews.com - November 13 at 3:34 AM
BRIEF-Kura Oncology Inc entered into amendment to its sales agreement with Cowen and CoBRIEF-Kura Oncology Inc entered into amendment to its sales agreement with Cowen and Co
www.reuters.com - November 11 at 3:49 PM
Kura Oncology to Host Investor Day on November 16, 2017Kura Oncology to Host Investor Day on November 16, 2017
finance.yahoo.com - November 11 at 3:49 PM
Leerink Swann Weighs in on Kura Oncology, Inc.s FY2017 Earnings (KURA)Leerink Swann Weighs in on Kura Oncology, Inc.'s FY2017 Earnings (KURA)
www.americanbankingnews.com - November 10 at 2:42 PM
Kura Oncology, Inc. (KURA) to Post FY2017 Earnings of ($1.52) Per Share, Oppenheimer Holdings ForecastsKura Oncology, Inc. (KURA) to Post FY2017 Earnings of ($1.52) Per Share, Oppenheimer Holdings Forecasts
www.americanbankingnews.com - November 10 at 2:34 PM
Kura Oncology, Inc. (KURA) Releases  Earnings Results, Misses Estimates By $0.01 EPSKura Oncology, Inc. (KURA) Releases Earnings Results, Misses Estimates By $0.01 EPS
www.americanbankingnews.com - November 8 at 4:44 PM
Kura Oncologys (KURA) "Buy" Rating Reiterated at CannKura Oncology's (KURA) "Buy" Rating Reiterated at Cann
www.americanbankingnews.com - November 8 at 9:50 AM

SEC Filings

Kura Oncology (NASDAQ:KURA) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Financials are not available for this stock.

Chart

Kura Oncology (NASDAQ KURA) Stock Chart for Saturday, February, 24, 2018

Loading chart…

This page was last updated on 2/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.